The incidence and prevalence change of inflammatory bowel disease in Jinan from 2005 to 2022 based on Jinan medical insurance cohort
10.3760/cma.j.cn101480-20240219-00025
- VernacularTitle:基于济南医保数据分析济南市2005—2022年炎症性肠病发病率及患病率的变化
- Author:
Yan ZHANG
1
;
Wenwen ZHENG
;
Leiqi XU
;
Han LIU
;
Xiaoyun YANG
;
Xiuli ZUO
;
Yanqing LI
Author Information
1. 山东大学齐鲁医院消化科，济南 250012
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Ulcerative colitis;
Crohn's disease;
Incidence;
Prevalence
- From:
Chinese Journal of Inflammatory Bowel Diseases
2025;09(2):136-142
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To identify the incidence and prevalence of inflammatory bowel disease (IBD) in the northern Chinese population of Jinan, Shangdong Province, along with its temporal trends from 2005 to 2022.Methods:By utilizing the data from the Jinan basic medical insurance system, a population-based IBD cohort was constructed. This facilitated the computation of both the incidence and prevalence rates of IBD, alongside their temporal trends throughout the 2005 to 2022 timeframe. The 95% confidence intervals were estimated using poisson regression.Results:The overall incidence rate of IBD showed a yearly increasing trend, with age-standardized incidence rates rising from 0.03/100 000 in 2005 to 5.39/100 000 in 2022. The age-standardized incidence rate of ulcerative colitis (UC) increased from 0.03/100 000 in 2005 to 4.97/100 000 in 2022. The age-standardized incidence rate of Crohn's disease (CD) rose from 0.05/100 000 in 2011 to 0.44/100 000 in 2022. The crude prevalence of IBD increased from 0.60/100 000 in 2005 to 32.39/100 000 in 2022. Specifically, the crude prevalence of UC increased from 0.60/100 000 in 2005 to 31.44/100 000 in 2022, while the crude prevalence of CD increased from 0.05/100 000 in 2011 to 1.19/100 000 in 2022.Conclusions:Analysis of recent medical insurance data reveals a continuous uptrend in both the incidence and prevalence of IBD in Jinan, a northern city in China. This underscores the urgent need for enhanced medical resources and healthcare guaruntee to ensure the well-being of individuals afflicted with IBD.
